Navigation Links
GSK Extends GeneGo License and Adds New Products

ST. JOSEPH, Mich., Feb. 5 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that GSK has extended their licensing agreement with GeneGo and have added additional capability. This will provide GSK researchers in Bioinformatics, R&D and clinical studies with global access to MetaCore, MapEditor and MetaBase. MetaCore is GeneGo's flagship platform for functional analysis of biological OMICs data featuring a comprehensive collection of pathway maps and network models for cellular processes and common diseases. MetaCore is used for target identification, validation, biomarker discovery and knowledge mining. GSK will also use the platform as a repository of all types of experimental data as well as resulting analyses. All of this information can be easily shared with individuals or groups. MetaBase is direct access to the manually curated database of pathways, networks, ontologies, medicinal chemistry and diseases covering human, mouse and rat. MapEditor is a powerful research tool for creating interactive custom maps which amalgamate MetaBase knowledge content with proprietary information and data.

"We have a good working relationship with GSK developing new products such as our pay as you go 1-2-3 Workflow," said Julie Bryant, GeneGo's VP of Business development. "We will continue to work closely developing new functionality, tools and content for GSK."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.5(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.5(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at

MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.

SOURCE GeneGo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Extends Tender Offer for Ventana
2. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
3. Organon Extends MetaCore License and Adds MetaLink
4. NASA Extends Cooperative Agreement With NSBRI
5. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
6. Roche Extends Tender Offer for Ventana
7. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
8. GeneGo Integrates With Cytoscape
9. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
10. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
11. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
Post Your Comments:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
Breaking Biology Technology:
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):